Janssen CarePath is your one source for access, affordability, and treatment support for your patients

Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on prescribed INVEGA HAFYERA™.

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET

Sign Up or Log In to the Provider Portal at JanssenCarePathPortal.com

Visit JanssenCarePath.com

Janssen CarePath can help you find out what affordability assistance may be available for your patients taking INVEGA HAFYERA™

Commercial Insurance

Janssen CarePath Savings Program can help eligible patients

pay $10 per dose

with an $8,000 maximum program benefit per calendar year or 2 doses, whichever comes first*

*Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their injection. See full eligibility requirements at InvegaHafyera.JanssenCarePathSavings.com.

Online enrollment of patients in the Savings program by you, the pharmacy, patient, or caregiver.

Providers and pharmacies can use Express Enrollment for Savings Program at JanssenCarePathPortal.com/express

Comprehensive Provider Portal for Savings Program and more at JanssenCarePathPortal.com

Patients and caregivers can enroll at MyJanssenCarePath.com/express

Goverment coverage options:

Medicare Part D Low Income Subsidy (LIS)

Full-benefit dual-eligible INVEGA HAFYERA™ patients may pay

$0 to $9.20 per dose1†

Through the Medicare Part D Program


Medicaid fee-for-service patients may pay

less than $6 per dose2‡

See full eligibility requirements for the low-income subsidy for Medicare Prescription Drug Coverage.

Medicaid Fee-for-Service is a state-specific program. Coverage for INVEGA HAFYERA™ may depend on the indication as well as other factors.
As this information varies by state, it is important to contact the state agency directly or consult its website to obtain product-specific coverage and other information.

REFERENCES: 1. Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2021 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, Table V-1. Accessed July 6, 2021. https://www.cms.gov/files/document/2021-announcement.pdf. 2. Medicaid benefits: Prescription drugs. Kaiser Family Foundation. Accessed July 6, 2021. https://www.kff.org/medicaid/state-indicator/prescription-drugs/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D